🔊CEOInterviews

Gael Touya on supply chain

From AptarGroup CEO: Consumer is still there, but our numbers reflect inventory adjustments post-COVID · · CNBC Television

“Part of this is really a supply chain effect coming out of COVID, our customers launched like crazy growth rates of 20% and more in fragrance. Now the sale through rate for the retail was not at those levels, more like 5%, 6%. Part of what you see in our numbers is an adjustment. Consumers is still there, and when you talk about China, it's not the consumer, but the growth isn't there that everybody expected. Vigorous rebound after COVID has not happened and our clients still hopeful the Chinese consumer will be more vigorous.”

Gael Touya
President of Aptar Pharma, APTARGROUP INC
Policy Impact supply chainCOVID-19 impactconsumer behaviorChina marketcosmetics industry

On , Gael Touya, President of Aptar Pharma at APTARGROUP INC, spoke about supply chain during AptarGroup CEO: Consumer is still there, but our numbers reflect inventory adjustments post-COVID on CNBC Television.

AptarGroup CEO: Consumer is still there, but our numbers reflect inventory adjustments post-COVID
Watch on YouTube
AptarGroup CEO: Consumer is still there, but our numbers reflect inventory adjustments post-COVID
CNBC Television
Watch on YouTube
Stephan Tanda, AptarGroup president and CEO, joins 'The Exchange' to discuss the company's quarterly earnings results, how ...
Gael Touya

About Gael Touya

President of Aptar Pharma · APTARGROUP INC

Gael Touya, President of Aptar Pharma at Aptargroup, has been discussing the company's performance and market conditions in recent interviews. Touya stated that the company's numbers reflect inventory adjustments following the COVID-19 pandemic, noting that while consumer demand remains, growth rates in fragrance and other segments have slowed from pandemic-era highs. He described tariffs as "neutral" for AptarGroup, citing the company's philosophy of serving regions from within the region)Skip. Touya also noted that the Chinese market has not seen the vigorous rebound some expected, but that Chinese brands are supplying the market and Asia remains a positive region for the company. Touya highlighted strong demand in the pharmaceutical sector, particularly for nasal sprays, inhalers, and sinus rinses, and said the company has invested over $180 million in capacity for biologic drugs including GLP-1 drugs. He identified weakness in the U.S. food and personal care home care segments, attributing it to changing consumer patterns and retailers working down COVID inventories. Touya noted that labor force issues have abated)Skip, and that the company's business is 75% outside the U.S., with travel retail driving growth in beauty and high-end fragrances. He described China as an important market and said the company is not in geopolitically sensitive areas.

Profile compiled from Gael Touya's verified public interviews and appearances. See all quotes & transcripts →

More from Gael Touya APTARGROUP INC (ATR) Full Transcript Explore All Executives